Sentences with phrase «non-hodgkin lymphoma patients»

Non-Hodgkin lymphoma patients are usually treated with rituximab (Rituxan ®, a monoclonal antibody) in combination with chemotherapy.

To block this signal, recent clinical studies have focused on inhibiting the activation of the B - cell receptor as a treatment for non-Hodgkin lymphoma patients, but with variable success.

Not exact matches

In December, Juno presented positive preliminary data on JCAR017 in patients with r / r aggressive non-Hodgkin lymphoma (NHL), reporting an 80 % overall response rate and a 60 % complete response rate.

Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].

The test, developed by the UQ Diamantina Institute's Professor Maher Gandhi, can predict how patients with a specific form of non-Hodgkin's lymphoma will respond to standard treatment.

The new drug will now be tested in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma in an early stage clinical trial.

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.

When Torres started the clinic, he expected to see a number of patients with liver cancers and non-Hodgkin's lymphoma, as these have documented associations with HCV of 48-fold and two - to three-fold increased risk, respectively.

In a study of 30 patients who received CTL019 for three different types of non-Hodgkin lymphoma, the researchers found that 59 percent of patients responded to the therapy (17 of 29, 15 of who experienced complete remissions of their disease).

Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Shah noted that cerebral edema has also been observed in clinical trials — among 6 ALL patients participating in the JUNO trials (and in 1 patient with non-Hodgkin lymphoma treated in the ZUMA - 1 phase II registration trial).

Hematopoietic stem cell mobilization in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease

Safety, Pharmacokinetics and Stem Cell Mobilization of TG - 0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients.

According to The National Cancer Institute, 8,260 people in the United States were diagnosed with Hodgkin lymphoma last year and approximately 1,070 patients with non-Hodgkin lymphoma died from the disease in 2017.

Plerixafor in combination with granulocyte - colony stimulating factor (G - CSF) has been approved for hematopoietic stem cell mobilization to the peripheral blood in patients with non-Hodgkin's lymphoma and multiple myeloma [54].

Dumler was only the second patient at MD Anderson and the third in the world to receive CAR T cells to treat non-Hodgkin's lymphoma on the multicenter clinical trial.

As many as 30 percent of patients who survive childhood Hodgkin lymphoma develop a secondary cancer after diagnosis, primarily breast cancer, non-Hodgkin lymphoma, thyroid cancer or acute leukemia.

Status: G100 is being studied in a fully - enrolled randomized Phase 2 trial in patients with follicular non-Hodgkin Lymphoma (FL) in combination with local radiation and Merck's anti-PD-1 agent, pembrolizumab, pursuant to a clinical collaboration with Merck.

The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma.

Surveillance computed tomography (CT) is usual practice for patients with aggressive non-Hodgkin lymphoma (aNHL) in complete remission (CR).

Immune Design entered into clinical collaboration agreements with Merck, known as MSD outside the U.S. and Canada, to evaluate the safety and efficacy of two Immune Design immuno - oncology investigative agents, G100 and LV305, separately combined with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in Phase 1 trials in patients with non-Hodgkin's lymphoma (NHL) and melanoma, respectively.